Rajesh Gontla, Ph.D.

Position: Postdoctoral fellow

Room no.: CP-02-110

Telephone no.: +49 (0)231 755 7053


Member of the group: 04/2013 – 08/2015 and 09/2017-till today

University degree: PhD in ….


Earlier positions:

Since 09/2017

Post-Doctoral Researcher, Technische Universität-Dortmund, Germany.  

"Design and synthesis of Nucleotide competitive inhibitors for the KRAS."

Principal Investigator: Prof. Dr. Daniel Rauh

09/2015- 08/2017

Post-Doctoral Researcher, Max-Planck Institute of Molecular Physiology -Dortmund, Germany.

"Synthesis of novel chiral Cp-Rh complexes and their potential applications in asymmetric catalysis."

Principal Investigator: Prof. Dr. Herbert Waldmann

(>2 years)  04/2013 - 07/2015  

Post-Doctoral Researcher, Technische Universität-Dortmund, Germany.

"Design and synthesis of small molecules as Covalent-Allosteric Akt inhibitors (CAAI’s)"

Principal Investigator: Prof. Dr. Daniel Rauh

(1.5 years)   10/2011 -03/2013

Senior Research Associate, Chemveda Life Sciences Pvt Ltd., Hyderabad, India. Process research and development (Process R&D) and CRO projects in Synthetic organic and medicinal chemistry.

(1 year)   06/2005 - 06/2006

Organic Chemistry Lecturer, NNS Vidya P.G College, Chirala, India.

"Organic Spectroscopy, Named reactions and reaction mechanism, Disconnection approach, Symmetry and Group theory."

(1 year)    05/2002 -05/2003  

Research Chemist, Divi’s Laboratories, Hyderabad, India.

"Maintaining High Vacuum Distillation plants and Vacuum tray dryers in bulk scale quantities."

Maintaining the BPR and MPR records for Q.A department.


Expertise: Organic synthesis

Off-Lab activities (hobbies): Playing Badminton and Chess, Music and Cooking.

Research projects:

Activating mutations in KRAS are found to be the most common mutations in various types of cancers. In particular, KRASG12C mutation is observed in most of the cancers. Various approaches are there to lock the KRAS in the inactive state but not reaches the affinity of GTP/GDP levels which is the major drawbacks of this area.  Even though the efforts of various research groups and industries across the globe from the last couple of decades to till date, there is no potent small molecule inhibitors are available for KRAS.  In this project we strongly focus on the Structure based drug design, synthesis of novel nucleotide competitive covalent inhibitors and evaluation in cellular viability assays.  



  1. General Enantioselective C−H Activation with Efficiently Tunable Cyclopentadienyl Ligands. Zhi-Jun Jia, Christian Merten, Rajesh Gontla, Constantin G. Daniliuc, Andrey P. Antonchick, Herbert Waldmann. Angew.Chem. Int.Ed. 2017, 56, 2429 –2434. (Selected as Hot Paper)
  2. Covalent-Allosteric kinase inhibitors. Jörn Weisner, Rajesh Gontla, Leandi van der Westhuizen, Sebastian Oeck, Julia Ketzer, Petra Janning, André Richters, Thomas Mühlenberg, Zhizhou Fang, Abu Taher, Verena Jendrossek, Stephen C. Pelly, Sebastian Bauer, Willem A. L. van Otterlo, Daniel Rauh (Angew. Chem.Int.Ed, 2015, 54, 35, 10313-10316). (Selected as Hot Paper)
  3. Enantioselective synthesis of the C5-C23 segment of biselyngbyaside, S. Chandrasekhar, G.Rajesh, T. Naresh, Tetrahedron Letters, 2013, 54, 252–255.
  4. First total synthesis of achaetolide. S.Chandrasekhar, S.V.Balaji, G. Rajesh, Tetrahedron letters, 2010, 51, 5164-5166.
  5. B(C6F5)3: an efficient catalyst for reductive alkylation of alkoxy benzenes and for synthesis of triarylmethanes using aldehydes. S. Chandrasekhar, Sanjida Khatun, G. Rajesh, Ch. Raji Reddy, Tetrahedron Letters, 2009, 50, 6693–6697.
  6. Tris(Pentafluorophenyl)borane: a mild and efficient catalyst for the chemoselective tritylation of alcohols.,Ch. Raji Reddy, G. Rajesh, S.V. Balaji, Tetrahedron letters, 2008, 6, 970-973.